Literature DB >> 22767499

Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection.

Nikolaos Papadantonakis1, Shinobu Matsuura, Katya Ravid.   

Abstract

Megakaryocytes (MKs), the platelet precursors, are capable of accumulating DNA greater than a diploid content as part of their cell cycle. MKs have been recognized as mediating fibrosis in a subset of hematologic malignancies, including acute megakaryoblastic leukemia and a subset of myeloproliferative neoplasms. The mechanisms responsible for fibrosis remain only partially understood. Past studies highlighted the role of growth factors in such pathologies, and recently, the protein lysyl oxidase (LOX) has been implicated in proliferation of MKs, ploidy and deposition of fibers. LOX was initially characterized as a protein responsible for the intermolecular cross-linking of elastin and collagen, and in recent years it has been identified as regulator of various pathologies, such as cancer and inflammation. Here, we review recent advances in the understanding of the contribution of MKs to the progression of myelofibrosis, highlighting the newly identified role of LOX.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22767499      PMCID: PMC3433087          DOI: 10.1182/blood-2012-02-402594

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  100 in total

Review 1.  Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell.

Authors:  Herbert M Kagan; Wande Li
Journal:  J Cell Biochem       Date:  2003-03-01       Impact factor: 4.429

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva.

Authors:  H H Hong; M I Uzel; C Duan; M C Sheff; P C Trackman
Journal:  Lab Invest       Date:  1999-12       Impact factor: 5.662

4.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.

Authors:  J L Villeval; K Cohen-Solal; M Tulliez; S Giraudier; J Guichard; S A Burstein; E M Cramer; W Vainchenker; F Wendling
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

5.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

Review 6.  From palliation to epigenetic therapy in myelofibrosis.

Authors:  Alessandro Rambaldi; Tiziano Barbui; Giovanni Barosi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

7.  Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype.

Authors:  N Pischon; J M Mäki; P Weisshaupt; N Heng; A H Palamakumbura; P N'Guessan; A Ding; R Radlanski; H Renz; T A L J J Bronckers; J Myllyharju; A M Kielbassa; B M Kleber; J-P Bernimoulin; P C Trackman
Journal:  Calcif Tissue Int       Date:  2009-05-21       Impact factor: 4.333

8.  Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.

Authors:  Claudia Vener; Nicola Stefano Fracchiolla; Umberto Gianelli; Rossella Calori; Franca Radaelli; Alessandra Iurlo; Sabrina Caberlon; Giancarla Gerli; Leonardo Boiocchi; Giorgio Lambertenghi Deliliers
Journal:  Blood       Date:  2007-11-20       Impact factor: 22.113

9.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528

10.  Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.

Authors:  Gina Kirsammer; Sarah Jilani; Hui Liu; Elizabeth Davis; Sandeep Gurbuxani; Michelle M Le Beau; John D Crispino
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

View more
  29 in total

1.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

2.  Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin.

Authors:  Alessandro Malara; Manuela Currao; Cristian Gruppi; Giuseppe Celesti; Gianluca Viarengo; Chiara Buracchi; Luigi Laghi; David L Kaplan; Alessandra Balduini
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

Review 3.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18

Review 4.  Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.

Authors:  Sophia S Lee; Srdan Verstovsek; Naveen Pemmaraju
Journal:  J Immunother Precis Oncol       Date:  2021-06-29

5.  Platelet polyphosphate induces fibroblast chemotaxis and myofibroblast differentiation.

Authors:  Patrick M Suess; Stephanie A Smith; James H Morrissey
Journal:  J Thromb Haemost       Date:  2020-09-10       Impact factor: 5.824

Review 6.  The role of extracellular matrix stiffness in megakaryocyte and platelet development and function.

Authors:  Orly Leiva; Catherine Leon; Seng Kah Ng; Pierre Mangin; Christian Gachet; Katya Ravid
Journal:  Am J Hematol       Date:  2018-01-12       Impact factor: 10.047

Review 7.  Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Authors:  B L Stein; R Swords; A Hochhaus; F Giles
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

8.  Megakaryocyte polyploidy is inhibited by lysyl oxidase propeptide.

Authors:  Alexia Eliades; Nikolaos Papadantonakis; Shinobu Matsuura; Rongjuan Mi; Manish V Bais; Philip Trackman; Katya Ravid
Journal:  Cell Cycle       Date:  2013-03-21       Impact factor: 4.534

9.  Cytosolic carboxypeptidase CCP6 is required for megakaryopoiesis by modulating Mad2 polyglutamylation.

Authors:  Buqing Ye; Chong Li; Zhao Yang; Yanying Wang; Junfeng Hao; Li Wang; Yi Li; Ying Du; Lu Hao; Benyu Liu; Shuo Wang; Pengyan Xia; Guanling Huang; Lei Sun; Yong Tian; Zusen Fan
Journal:  J Exp Med       Date:  2014-10-20       Impact factor: 14.307

10.  Does angiogenesis matter in primary myelofibrosis?

Authors:  Paulo Vidal Campregher
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.